More Americans Support Stem Cell Research
On the eve of the introduction of a bill in Congress by Rep. Michael Castle, R-DE, and Rep. Diana DeGette, D-CO, to expand federal stem cell research, the RFA survey shows that a growing number of Americans favor going beyond President Bush's strict limits on stem cell research for medical research purposes. The level of public support for wider federal stem cell research now is slightly higher than it was after the death last spring of former President Ronald Reagan, whose widow, Nancy Reagan, called for the elimination of barriers to the exploration of stem cells for possible medical treatments.
Another factor identified by the survey as driving the public's support for stem cell research: The recent announcement that most or all of the stem cell lines approved for federal research purposes have been compromised, and thereby rendered useless for the pursuit of possible medical cures.
Civil Society Institute President Pam Solo said: "These findings clearly show that stem cell research is not an issue that is going to go away. If anything, the level of public backing is rising, edging up from the high-water mark of support brought about by the extensive public discussion about stem cell research in the wake of the passing of former President Ronald Reagan. The growing number of state-level ballot initiatives and legislative pushes means that federal lawmakers have two choices: either get out front and lead on this issue or be overtaken by all of the clamoring for stem cell research that is bubbling up from the grassroots level."
In August 2001, the Bush administration imposed a major new restriction on federal funding for embryonic stem cell research. The restriction meant that research on stem cell lines created before August 2001 could receive funding, but prohibited support for research on stem cell lines developed after that date.
Most read news
Organizations
Related link
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.